The role of vasoactive intestinal peptide in pulmonary diseases

Hong-Lin Zhong; Pei-Ze Li; Di Li; Cha-Xiang Guan; Yong Zhou

doi:10.1016/j.lfs.2023.122121

The role of vasoactive intestinal peptide in pulmonary diseases

Life Sci. 2023 Nov 1:332:122121. doi: 10.1016/j.lfs.2023.122121. Epub 2023 Sep 22.

Authors

Hong-Lin Zhong¹, Pei-Ze Li¹, Di Li¹, Cha-Xiang Guan², Yong Zhou³

Affiliations

¹ Department of Physiology, School of Basic Medical Science, Central South University, Changsha, Hunan 410078, China.
² Department of Physiology, School of Basic Medical Science, Central South University, Changsha, Hunan 410078, China. Electronic address: guanchaxiang@csu.edu.cn.
³ Department of Physiology, School of Basic Medical Science, Central South University, Changsha, Hunan 410078, China. Electronic address: zhouyong421@csu.edu.cn.

PMID: 37742737
DOI: 10.1016/j.lfs.2023.122121

Abstract

Vasoactive intestinal peptide (VIP) is an abundant neurotransmitter in the lungs and other organs. Its discovery dates back to 1970. And VIP gains attention again due to the potential application in COVID-19 after a research wave in the 1980s and 1990s. The diverse biological impacts of VIP extend beyond its usage in COVID-19 treatment, encompassing its involvement in various pulmonary and systemic disorders. This review centers on the function of VIP in various lung diseases, such as pulmonary arterial hypertension, chronic obstructive pulmonary disease, asthma, cystic fibrosis, acute lung injury/acute respiratory distress syndrome, pulmonary fibrosis, and lung tumors. This review also outlines two main limitations of VIP as a potential medication and gathers information on extended-release formulations and VIP analogues.

Keywords: Acute respiratory distress syndrome; Chronic obstructive pulmonary disease; Lung cancer; Pulmonary arterial hypertension; Vasoactive intestinal peptide.

Publication types

Review

MeSH terms

Humans
Lung Diseases* / drug therapy
Pulmonary Disease, Chronic Obstructive* / drug therapy
Vasoactive Intestinal Peptide* / therapeutic use

Substances

Vasoactive Intestinal Peptide